Andersson TB - Search Results

1

In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.

Gopaul VS, Vildhede A, Andersson TB, Erlandsson F, Lee CA, Johansson S, Hilgendorf C. Gopaul VS, et al. Among authors: andersson tb. J Pharmacol Exp Ther. 2021 Aug;378(2):108-123. doi: 10.1124/jpet.121.000549. Epub 2021 Jun 1. J Pharmacol Exp Ther. 2021. PMID: 34074714

2

High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.

Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB. Karlsson JE, et al. Among authors: andersson tb. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. Drug Metab Dispos. 2010. PMID: 20071452

3

Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function.

Miliotis T, Ali L, Palm JE, Lundqvist AJ, Ahnoff M, Andersson TB, Hilgendorf C. Miliotis T, et al. Among authors: andersson tb. Drug Metab Dispos. 2011 Dec;39(12):2440-9. doi: 10.1124/dmd.111.040774. Epub 2011 Sep 23. Drug Metab Dispos. 2011. PMID: 21949244

4

Primary Human Hepatocyte Spheroid Model as a 3D In Vitro Platform for Metabolism Studies.

Kanebratt KP, Janefeldt A, Vilén L, Vildhede A, Samuelsson K, Milton L, Björkbom A, Persson M, Leandersson C, Andersson TB, Hilgendorf C. Kanebratt KP, et al. Among authors: andersson tb. J Pharm Sci. 2021 Jan;110(1):422-431. doi: 10.1016/j.xphs.2020.10.043. Epub 2020 Oct 26. J Pharm Sci. 2021. PMID: 33122050 Free article.

5

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.

Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG. Bredberg E, et al. Among authors: andersson tb. Clin Pharmacokinet. 2003;42(8):765-77. doi: 10.2165/00003088-200342080-00005. Clin Pharmacokinet. 2003. PMID: 12846597 Clinical Trial.

6

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.

Jones BC, Rollison H, Johansson S, Kanebratt KP, Lambert C, Vishwanathan K, Andersson TB. Jones BC, et al. Among authors: andersson tb. Drug Metab Dispos. 2017 Jan;45(1):35-41. doi: 10.1124/dmd.116.072025. Epub 2016 Oct 24. Drug Metab Dispos. 2017. PMID: 27777246 Review.

7

Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.

Ulvestad M, Nordell P, Asplund A, Rehnström M, Jacobsson S, Holmgren G, Davidson L, Brolén G, Edsbagge J, Björquist P, Küppers-Munther B, Andersson TB. Ulvestad M, et al. Among authors: andersson tb. Biochem Pharmacol. 2013 Sep 1;86(5):691-702. doi: 10.1016/j.bcp.2013.06.029. Epub 2013 Jul 12. Biochem Pharmacol. 2013. PMID: 23856292

8

Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system.

Ulvestad M, Darnell M, Molden E, Ellis E, Åsberg A, Andersson TB. Ulvestad M, et al. Among authors: andersson tb. J Pharmacol Exp Ther. 2012 Oct;343(1):145-56. doi: 10.1124/jpet.112.195750. Epub 2012 Jul 12. J Pharmacol Exp Ther. 2012. PMID: 22789711

9

Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.

Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, Hjelmesæth J, Andersson TB, Sandbu R, Christensen H. Ulvestad M, et al. Among authors: andersson tb. Clin Pharmacol Ther. 2013 Mar;93(3):275-82. doi: 10.1038/clpt.2012.261. Epub 2012 Dec 27. Clin Pharmacol Ther. 2013. PMID: 23361102

10

In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system.

Darnell M, Ulvestad M, Ellis E, Weidolf L, Andersson TB. Darnell M, et al. Among authors: andersson tb. J Pharmacol Exp Ther. 2012 Oct;343(1):134-44. doi: 10.1124/jpet.112.195834. Epub 2012 Jul 9. J Pharmacol Exp Ther. 2012. PMID: 22776955

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

114 results

Search Page